Role of Maraviroc and/or Rapamycin in Aging Liver Processes
Research Square (Research Square)(2022)
Abstract
Abstract Background: Cellular senescence and low-grade inflammation favor the acceleration of aging. The liver is an essential metabolic organ because changes related to its function are related to age-related diseases. The objective of this study was to evaluate the effects of maraviroc (MVC) and/or rapamycin (RAPA) on liver tissue in an experimental model of aging in mice.Materials and methods: Eighty male homozygous IL10KO mice were randomly assigned to one of 4 groups (n= 20): i) IL10KO group (IL10KO); ii) IL10KO mice that received MVC in drinking water (MVC group), iii) IL10KO mice that received RAPA in drinking water (RAPA group), and iv) MVC-RAPA group that received MVC and RAPA in drinking water. Liver samples were analyzed. Gene expression quantification, western blotting and histopathological analyses were also performed.Results: The proinflammatory cytokines IL-6 and IL-18 were decreased in the MVC and MVC/RAPA groups, and TNF-α was decreased in all therapeutic groups. Galactosidase beta-1, a senescence biomarker, was also significantly reduced in all therapeutic groups, as were NK-kB1 and NF-kB2. In all groups, mTOR and CCL5 were significantly reduced. CCR5 expression was decreased in the MVC and MVC/RAPA groups.Conclusions: MVC and RAPA may protect against some factors involved in liver aging. More studies will be necessary to verify their clinical applications.
MoreTranslated text
Key words
aging liver processes,rapamycin,maraviroc
AI Read Science
Must-Reading Tree
Example
![](https://originalfileserver.aminer.cn/sys/aminer/pubs/mrt_preview.jpeg)
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined